Skip to main content
Loading

Advancing neoantigen identification and immune monitoring: From discovery to clinical validation

25 Sep 2025
Immune Biomarkers
  • Address the challenge of accurately predicting truly immunogenic neoantigens despite advances in AI and sequencing technologies.
  • Discuss the difficulty of experimentally validating predicted neoantigens and distinguishing between patient-specific and shared targets.
  • Explore the limitations in immune monitoring techniques for reliably tracking neoantigen-specific responses during treatment.
  • Examine the translational hurdles in scaling and validating personalized neoantigen therapies for clinical use.
Industry Expert
Léila Delamarre, Distinguished Scientist and Director, Cancer Immunology Discovery - Genentech